Objective: Thyroxine (T 4 ) requirement after total thyroidectomy for differentiated thyroid carcinoma (DTC) is a debated issue. As most of the studies in the area have been retrospective and/or performed with heterogeneous therapeutic approaches, we designed our study to determine T 4 requirement in the same patients and treatment settings, before and after total thyroidectomy. Design, patients and methods: This was a longitudinal study including 23 goitrous patients treated with T 4 in an individually tailored fashion. All patients exhibited a stable TSH (median TSHZ0.28 mU/l) at a stable T 4 dose for at least 1 year before surgery (median T 4 doseZ1.50 mg/kg per day). The patients underwent total thyroidectomy based on cancer suspicion or compressive symptoms. Eventually diagnosed as having DTC (pT1b-pT2N0) and following surgical and radiometabolic treatment, they were treated with the same pre-surgical doses of T 4 . Results: Three months after surgery,using the same pre-surgical dose, median TSH increased up to 5.38 mU/l (P!0.0001) and so the T 4 dose had to be increased (median T 4 doseZ1.95 mg/kg per day; C30%; P!0.0001). Once divided by patients' age, we observed that, after thyroidectomy and maintaining the same pre-surgical dose, serum TSH significantly increased both in younger and in older patients (median TSHZ4.57 and 6.11 mU/l respectively). Serum TSH was restored to the pre-surgical level by increasing the dose up to 1.95 and 1.77 mg/kg per day (C25 and C21%) respectively. Conclusions: Following the same treatment regimen, a thyroidectomized patient requires one-third higher therapeutic T 4 dose than before surgery. Despite this increase, the dose of T 4 needed in our patients remains significantly lower than that previously described in athyreotic patients.
Introduction
Levothyroxine (L-T 4 ) sodium is commonly used to restore thyroid function in hypothyroid patients, in the management of non-toxic multinodular goiter (NTMG) or after total thyroidectomy for differentiated thyroid cancer (DTC) (1, 2, 3, 4) . The main goal of T 4 treatment is to promptly achieve the therapeutic target, avoiding overor under-treatments (5), but some patients require several dose adjustments prior to attaining an adequate pharmacological T 4 homeostasis (6, 7) . Despite some reports on the inability of T 4 alone to warrant euthyroidism in all tissues (8) , L-T 4 monotherapy is as yet the preferred treatment (9) . Oral T 4 is asymmetrically deiodinated to triiodothyronine (T 3 ) in peripheral tissues and mimics a nearly physiological T 4 /T 3 ratio (9, 10) . In keeping with the American Thyroid Association (ATA) and European Thyroid Association (ETA) guidelines, patients with DTC, after total thyroidectomy, should be treated with T 4 according to risk stratification (2, 11) . In patients with a low risk of recurrences of DTC, T 4 treatment in semisuppressive mode is required in the first year after surgery, according to ATA guidelines (2, 5) . Several studies dealing with T 4 requirement have been carried out on patients with primary hypothyroidism, with or without thyroid in situ (see (6, 9) for a review). Some of these studies focused on factors affecting the therapeutic dose, such as body weight (6, 12) , BMI (13) , amount of residual thyroid tissue, patients' age and drugs (14, 15, 16) , and only a fraction of them examined T 4 requirement after total thyroidectomy (7, 8, 9, 10, 11) . However, most of these latter reports were retrospective and/or compared results obtained in different groups of patients (15, 16, 17) , and/or in heterogeneous therapeutic settings (7, 16) . At best, some authors used empirical and continuously adjusted T 4 doses and mathematical models to predict the postsurgical dose (16, 17) . A prospective pre-and post-surgical study on the same patients was carried out by Jonklaas et al. (18) who showed similar T 3 levels before and after surgery. However, no conclusions were drawn about T 4 requirements, as patients were not treated before surgery. Therefore, our study was aimed at determining the T 4 requirement in the same treatment setting and in the same patients, before and after total thyroidectomy.
Patients and methods
A total of 1538 Caucasian outpatients living in a mild iodine-deficient area, with NTMG, were examined in our referral center for thyroid diseases from 2008 to 2012. About half of them required T 4 treatment and all patients were treated with the same brand of T 4 . Of these, 158 patients underwent thyroid surgery because of cancer suspicion or compressive symptoms (19) . All these patients underwent total thyroidectomy and, of these, 83 patients had thyroid cancer. Among these, 36 patients had a diagnosis of papillary thyroid carcinoma (PTC) with a low risk of recurrence (2) . Twenty-three patients (19 women and four men; median ageZ51 years) were eligible for our study according to the following criteria: i) they have had NTMG treated with an individually tailored semi-suppressive dose of L-T 4 for at least 1 year; ii) have a low-risk DTC requiring T 4 treatment in semi-suppressive mode (2). Exclusion criteria were: i) a history of hyperthyroidism or toxic nodular goitre as well as the presence of autonomously functioning areas in the thyroid scan; ii) the recent use (!6 months) of drugs known to interfere with thyroid homeostasis (20) ; iii) the presence of concomitant gastrointestinal disorders (gastritis related to Helicobacter pylori infection, atrophic gastritis, coeliac disease, lactose intolerance, etc.) known to increase L-T 4 requirement (21, 22, 23) ; iv) being pregnant.
Among the 23 patients enrolled, 18 patients had a pT2 N0 PTC and five patients had a pT1b N0 PTC, according to the TNM classification from the International Union against Cancer. According to ATA guidelines for the follow-up of DTC at low risk of recurrences (2), all these patients received radioiodine (RAI) treatment after surgery (30 mCi) and T 4 therapy had been reinstituted in a semisuppressive dose fashion (target serum thyroid-stimulating hormone (TSH)Z0.1-0.5 mU/l).
All patients were disease-free after 1 year from the RAI ablation (undetectable serum thyroglobulin and a negative neck ultrasonography). Clinical features of the study patients are described in Table 1 .
Study design
All patients with NTMG were treated with an individually tailored dose of T 4 , as previously described (21, 22, 23, 24) and in semi-suppressive mode (target serum TSHZ0.1-0.5 mU/l) (2). The individually tailored dose is the dose of T 4 which is administered following a standardized assumption procedure and titrated on the basis of patient's age, weight, BMI, the amount of residual thyroid tissue and the ability to absorb the hormone (12, 14, 15, 21, 22, 23, 24) . All patients were treated with the same brand of oral and agreed to take T 4 under fasting conditions, abstaining from eating or drinking anything other than water for at least 1 h after treatment. Before surgery, once target TSH had been reached, the dose of T 4 was not changed and serum TSH was measured every 6 months. All these goitrous patients were followed for at least 1 year before surgery (mean period of treatment 4G2 years). Compliance of enrolled patients was checked at every control and confirmed by the stability of serum TSH at constant dose. After surgery and radioiodine treatment, T 4 treatment has been restarted at the same presurgical dose with identical criteria for T 4 assumption and TSH and thyroid hormones checked every 3 months. When necessary, the dose of T 4 has been subsequently increased to reach the therapeutic target. The dose of T 4 required to obtain the therapeutic goal was normalized by patient's age and body weight both during pre and post surgical period. So far, we compared the T 4 requirement in the same patients, before and after total thyroidectomy.
Study has been conducted upon written informed consent and as part of the diagnostic and therapetic workup of the patients involved, according to the local ethical rules and to the guidelines in the Declaration of Helsinki.
Methods
Serum TSH, free T 4 (FT 4 ) and free T 3 (FT 3 ) levels were analyzed at the same time. Serum TSH levels were measured by commercial kit (Thermo Scientific, BRAHMS TSH RIA, Hennigsdorf, Germany) (normal range: 0.4-4.0 mU/l; sensitivity: 0.04 mU/l; intra-assay and inter-assay variation were 2.5 and 4.1%, respectively). Levels of serum FT 4 were detected by commercial kit (Thermo Scientific, BRAHMS FT 4 RIA) (normal range: 10-25 pmol/l, which is the equivalent of 0.78-1.94 ng/dl), as the levels of serum FT 3 (normal range 3.5-8.1 pmol/l or 2.3-5.3 pg/ml). Serum anti-thyroid peroxidase antibodies were measured by commercial assay (Thermo Scientific, BRAHMS anti-TPO) (normal range: !60 U/ml).
The diagnosis of NTMG
The diagnosis of NTMG was based on clinical and ultrasonographical features, normal serum iodothyronines and TSH, the absence of serum antiperoxidase antibodies, normal radioiodine uptake and thyroid scan. All patients had goitre WHO stage 1A or 1B and at least 2 nodules O1 cm (21).
Thyroid surgery
Total thyroidectomy was performed at 'Sapienza' University of Rome, Policlinico Umberto I, Rome, Italy, by a highly experienced head and neck surgeon (Fabrizio Frattaroli, MD).
Completeness of thyroidectomy was checked by neck ultrasound, performed almost 6 months after surgery. No patients had evidence of thyroid tissue remnant O0.5 ml.
Statistical analysis
Data are expressed as a median with relative interquartile range (IQR). The median values were compared using the Individual T 4 dose/weight in all 23 patients before and after thyroidectomy.
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Results
A total of 23 patients with NTMG in treatment with T 4 underwent total thyroidectomy and DTC was histologically diagnosed. None of them was hypothyroid at the baseline (median serum TSHZ1.20 mU/l; median serum FT 3 Z3.3 pg/ml and FT 4 Z1.06 ng/dl). Once treated for NTMG, at a median dose of T 4 of 1.50 mg/kg per day (IQ1-IQ3Z1.33-1.58 mg/kg per day), these patients exhibited a stable TSH at stable T 4 dose for at least 1 year. In the last control before surgery these patients had a median TSH of 0.28 mU/l (IQ1-IQ3Z0.19-0.55 mU/l) and a median serum FT 4 of 1.46 ng/dl and FT 3 of 3.11 pg/ml. Following total thyroidectomy and radiometabolic procedures, T 4 treatment had been resumed at the presurgical dose in each patient and thyroid function was tested within 3 months after the treatment restart. Despite the median weight (66 kg) and the T 4 dose before and after surgery was identical to presurgical period, only 2/23 patients reached the target TSH, while in the remaining 21 patients a significant increase of serum TSH has been observed. The overall median TSH was 5.38 mU/l (IQ1-IQ3Z3.63-7.87 mU/l; P!0.0001) (Fig. 1) . To maintain the therapeutic goal, as required both for DTC risk stratification and for the design of the study, T 4 dose had been adjusted in the 21 patients and, within three to 6 months period, the individual TSH was in the expected range. The median TSH value was then comparable to the presurgical one (0.21 mU/l; IQ1-IQ3Z 0.13-0.44 mU/l; PZNS) (Fig. 1) . To obtain this goal, the individual T 4 dose was increased in these patients to a different extent (Fig. 2) . After 1 year, the median daily dose of T 4 was 1.95 mg/kg per day (IQ1-IQ3Z1.71-1.98 mg/kg per day), significantly higher than the presurgical one by 30% (1.50 vs 1.95 mg/kg per day; P!0.0001) (Fig. 3) . To note, the median values of serum FT 4 and FT 3 were not changed throughout the study and were not affected by the increased T 4 dose (PZ0.5111; PZ0.4076, respectively) (Fig. 4) . More specifically, only two patients out of 23 showed FT 3 values below normal and none showed subnormal FT 4 . Since T 4 metabolism is slowed down in elderly patients (12) and the dose of T 4 should be accordingly reduced, age may represent a confounding factor. So far, patients were subdivided into two agerelated groups: under 50 years of age (nZ11) and 50 years of age or older (nZ12) and the pre-and post-surgical dose has been compared accordingly. Clinical features of these patients are described in Table 2 .
Prior to surgery, a median TSH of 0.34 mU/l has been obtained in younger patients using a median T 4 dose of 1.56 mg/kg per day (IQ1-IQ3Z1.38-1.61 mg/kg per day). After surgery, maintaining the same pre-surgical dose, serum TSH significantly increased in all patients but one (medianZ4.57 mU/l; PZ0.0022). T 4 treatment was then increased and serum TSH was restored to normal (medianZ0.18 mU/l) in all patients by increasing the median T 4 dose up to 1.95 mg/kg per day (IQ1-IQ3Z 1.87-1.98 mg/kg per day; C25%; PZ0.0003) (Fig. 5a ). In patients aged 50 years or older, median presurgical TSH was 0.21 mU/l and was attained with a median T 4 dose of 1.46 mg/kg per day (IQ1-IQ3Z1.23-1.52 mg/kg per day). Post-surgical serum TSH significantly increased in all patients but one (median TSHZ6.11 mU/l), and again it was restored to presurgical levels (0.27 mU/l) by increasing the T 4 dose. In this group, the median daily T 4 dose was 1.77 mg/kg per day (IQ1-IQ3Z1.67-1.96 mg/kg per day; C21%; PZ0.0002) (Fig. 5b) . In these age-related groups of patients, serum FT 4 levels were also similar prior to surgery and after the increase of the T 4 dose (PZNS). On the contrary, we observed that postsurgical FT 3 values were lower in three out of 11 young patients (27%) and in seven out of 12 older patients (58%) as compared to presurgical values. Despite these apparent differences, the median pre-and post-surgical FT 3 levels were not statistically different in both age-related groups (PZ0.7621 and PZ0.2185 respectively).
Discussion
There is a general consensus that an increased need for T 4 is observed in patients following thyroidectomy (7, 15, 16, 17) . However, the quality of evidence in the guidelines prepared by the ATA task force was only moderate (25) , because of the differences in the design of the studies, in the characteristics of patients and in the standardization of treatments. Also, a wide range of daily T 4 requirements and very high doses were reported (see (25) for review). Some of these limitations were overcome in our study in that: i) all patients were treated and stabilized before surgery using an individually tailored dose and the compliance of patients was carefully checked; ii) the need for T 4 has been measured for the first time in the very same patient before and after thyroidectomy with identical criteria for T 4 assumption; iii) all patients were treated with a semi-suppressive T 4 dose whose target is a narrow TSH range. This approach increased the reliability of our results, namely the daily T 4 requirement in the same patients, thus avoiding interindividual variability. So far, in our prospective study, a remarkably lower daily T 4 requirement has been noticed. An increased dose of T 4 by about 30% was sufficient to attain target TSH in our patients after thyroidectomy. This increase has been ascribed to the need for replacement of direct glandular T 3 production (26), which in post-surgical athyreotic patients is no longer available. In our study, following total thyroidectomy, patients also received radioiodine treatment for DTC, allegedly leading to the absence of functional thyroid tissue. The absence of thyroid-derived T 3 in these patients led some authors to assume that a partial T 3 deficiency may be an issue during L-T 4 treatment after surgery (8, 26) . However, in a prospective study carried out in the same patients before and after thyroidectomy, no difference has been shown by comparing FT 3 levels before and after replacement T 4 dose (18) . This suggests that T 3 administration may be not needed to maintain serum T 3 values at their endogenous pre-surgical levels. According to Jonklaas et al. (18) , our present data confirm the lack of differences in median T 3 values before and after surgery, following an individually tailored T 4 treatment. However, we noticed that, mainly in the older group, some patients showed apparently lower 
Figure 5
Median T 4 dose/weight before and after thyroidectomy (a) in patients aged !50 years and (b) in patients aged O50 years.
Mann-Whitney non-parametric test has been used for statistical analysis.
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Clinical Study S C Del Duca, M G Santaguida and others (27, 28, 29) . Escobar-Morreale et al. (27) even suggested that athyreotic patients may have a differential organ responsiveness to suboptimal thyroid hormone concentrations. Now, the question arises about the crucial role of D2 in the conversion of T 4 in T 3 in peripheral tissues (29, 30) . In fact, these gate-keeper enzymes (31) are alleged to counteract the loss of thyroid-derived T 3 with an increase of extrathyroidal type 2 deiodinase activity (29, 30) . A type 2 deiodinase polymorphism has been described in patients where a defective D2 activity was associated with an increased need for T 4 (32) . However, it seems not sufficient to explain why some patients may not fully recover despite an appropriate dose of T 4 (8, 33) . On this ground, some studies analyzed the effects of combined T 3 /T 4 treatment in hypothyroid patients, including those who have undergone thyroidectomy (10, 27, 28, 33, 34) , but mostly failed to show advantages when compared with L-T 4 therapy alone (10, 25, 34) . In summary, our study provided evidence for the first time and in a consistent human model that, after total thyroidectomy, the therapeutic dose of T 4 must be increased by 1/3 as compared with the pre-surgical one. This additional amount of T 4 may be the substrate for the peripheral deiodinase network to compensate for the absence of T 3 production from the gland. Despite this increase, the individually tailored T 4 requirement in our patients remains significantly lower than previously described, thereby reducing the risk of over-treatment.
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